ViMove is being used to validate patient outcomes in Pfizer supported study 
CLICK HERE TO REQUEST MORE INFORMATION ABOUT ViMove

Melbourne, Australia.  29 June 2017.  Melbourne, Australia: dorsaVi Ltd (ASX: DVL) has today announced that ViMove is being used to assess the impact on movement and muscle activity of an over the counter product in a Pfizer supported study.


Prior to having access to ViMove, healthcare companies were reliant on subjective measures and patient reported outcomes such as questionnaires. Insurers and regulatory bodies are seeking objective and functional outcome measures in an attempt to prioritise the funding or approval of evidence based interventions. ViMove provides objective data to inform the benefits of certain treatments or interventions.


dorsaVi CEO Dr Andrew Ronchi said: “The importance of using a FDA cleared device to capture clinically relevant data is being recognised by both pharmaceutical and medical device companies. Apart from the current study, several medical device companies are using ViMove to investigate the functional outcomes their products have on patients. ViMove is used to measure patients before and after treatments or procedures to objectively track their improvement.”

Request more information about ViMove

CONTACT ME FOR MORE INFORMATION

Randomised Controlled Trial with dorsaVi technology finds back pain patients monitored and treated using dorsaVi's sensors had significant, sustained improvements in pain and function.

Recent news: What's happening at dorsaVi 

ViPerform and the NFL: How Loren Landow uses objective data to assess risk of injury

Fix the following errors:
Hide